Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Chief Medical Officer | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,713 |
Reported balance
After 2026-05-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-18 · Sale · Disposed 45,887 · Balance 272,713 F1: Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 20:30 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 45,887 | $0.90 | $41,146.87 |
DisclosureSEC source: 0001916853-26-000002 · ownership.xml · nonDerivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,713 F1 · security: Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person. Read SEC document |
| November 16, 2025 Filed Nov 17, 2025 22:51 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 311,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-052720 · wk-form4_1763419881.xml · nonDerivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,600 F1 · security: The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027. Read SEC document |
| April 10, 2025 Filed Apr 14, 2025 13:00 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 7,500 | $1.55 | $11,625.00 |
DisclosureSEC source: 0001818382-25-000049 · wk-form4_1744635605.xml · nonDerivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:34 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 283,101 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001818382-25-000015 · wk-form4_1737668036.xml · derivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,101 Underlying: Common Stock · 283,101 shares Expires 2035-01-21 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 283,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001818382-23-000195 · wk-form4_1702415399.xml · derivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,000 Underlying: Common Stock · 283,000 shares Expires 2033-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:13 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 91,120 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001818382-22-000198 · wf-form4_167087961711138.xml · derivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,120 Underlying: Common Stock · 91,120 shares Expires 2032-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:40 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 144,927 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001818382-22-000023 · wf-form4_164919121747205.xml · derivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,927 Underlying: Common Stock · 144,927 shares Expires 2032-04-04 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on April 4, 2023, after which 1/48 of the option will become exercisable on the 4th of each month through August 4, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.